Among these women, at 5 years, the overall
and disease-free survival rates in the
adjuvant therapy group were 88 percent
and 83 percent, respectively, while the corresponding rates in the observation group were 74 percent and 61 percent. Once again, the differences persisted at 10 years.
The current findings support the use of adjuvant oophorectomy and tamoxifen in premenopausal women, particularly those with ER-positive tumors, the investigators conclude.